BlueGnome to Market Rubicon Technology for IVF Studies | GenomeWeb

NEW YORK (GenomeWeb News) – BlueGnome will market Rubicon Genomics' technology along with its microarray-based aneuploidy chromosome screening and detection systems under a new non-exclusive agreement, Rubicon said today.

BlueGnome will market the PicoPlex technology to in vitro fertilization researchers under the name SurePlex DNA Amplification System. The PicoPlex technology can obtain "the same amount of genomic data from one cell as from 10,000," the company said, enabling researchers to produce five micrograms of amplified DNA in under three hours.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.